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Norovirus-Specific Memory T Cell
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Maria Malm†, Kirsi Tamminen†, Timo Vesikari and Vesna Blazevic*
Vaccine Research Center, University of Tampere, Tampere, Finland
Norovirus (NoV) is a leading cause of acute gastroenteritis in people of all ages
worldwide. NoV-specific serum antibodies which block the binding of NoV virus-like
particles (VLPs) to the cell receptors have been thoroughly investigated. In contrast,
only a few publications are available on the NoV capsid VP1 protein-specific T cell
responses in humans naturally infected with the virus. Freshly isolated peripheral blood
mononuclear cells of eight healthy adult human donors previously exposed to NoV
were stimulated with purified VLPs derived from NoV GII.4-1999, GII.4-2012 (Sydney),
and GI.3, and IFN-γ production was measured by an ELISPOT assay. In addition,
76 overlapping synthetic peptides spanning the entire 539-amino acid sequence of
GII.4 VP1 were pooled into two-dimensional matrices and used to identify putative
T cell epitopes. Seven of the eight subjects produced IFN-γ in response to the
peptides and five subjects produced IFN-γ in response to the VLPs of the same
origin. In general, stronger T cell responses were induced with the peptides in each
donor compared to the VLPs. A CD8+ T cell epitope in the shell domain of the VP1
(134SPSQVTMFPHIIVDVRQL151) was identified in two subjects, both having human
leukocyte antigen (HLA)-A∗02:01 allele. To our knowledge, this is the first report using
synthetic peptides to study NoV-specific T cell responses in human subjects and identify
T cell epitopes.
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INTRODUCTION
Norovirus (NoV) is recognized as a leading cause of acute gastroenteritis in children and adults
worldwide (Hall et al., 2016). According to a recently published WHO report, NoVs caused
120 million cases of diarrheal diseases, more than any other foodborne or infectious agent
(Havelaar et al., 2015). These non-enveloped RNA viruses belonging to Caliciviridae family are
highly infectious and cause frequent outbreaks that can be serious to individuals with underlying
conditions, the elderly, and young children (Hall et al., 2016). Currently, there is no cure or
preventive vaccine available against NoV gastroenteritis.
Abbreviations: APC, allophycocyanin; BV, baculovirus; CEF, cytomegalovirus, Epstein–Barr Virus and Influenza virus;
CTL, cytotoxic T lymphocyte; ELISA, enzyme-linked immunosorbent assays; ELISPOT, enzyme-linked immunosorbent
spot; FITC, fluorescein isothiocyanate; HBGA, histo-blood group antigen; HIV-1, human immunodeficiency virus-1; HLA,
human leukocyte antigen; HRP, horseradish peroxidase; ICS, intracellular cytokine staining; IFN-γ, interferon gamma; IL-2,
interleukin-2; NoV, Norovirus; OD, optical density; ORF, open reading frame; OVA, ovalbumin; PBMCs, peripheral blood
mononuclear cells; PBS, phosphate buffered saline; PE, phycoerythrin; SEB, staphylococcal enterotoxin B; SFC, spot-forming
cells; SYD, Sydney; Th, T helper; TNF-α, tumor necrosis factor alpha; VLP, virus-like particle.
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The∼7.6 kb-long single-stranded positive-sense RNA genome
has three ORFs that encode for the replicase polyprotein (ORF-
1), major VP1 capsid protein (ORF-2), and minor capsid
protein VP2 (ORF-3; Prasad et al., 1999). NoVs are genetically
classified into seven genogroups (GI to GVII), which are
further divided into genotypes based on capsid VP1 amino acid
sequence diversity (Kroneman et al., 2013; Vinje, 2015). NoV
genotypes associated with human infections belong primarily
to GI (9 genotypes) and GII (22 genotypes), with a >50%
divergence of the VP1 at amino acid-level (Zheng et al., 2006;
Kroneman et al., 2013). Variants of the most efficiently evolving
GII.4 genotype, with approximately >95% homology in VP1
sequences, have predominated over the last two decades (Bok
et al., 2009). VP1 consists of a shell (S) domain, a hinge region,
and a protruding (P) domain, the latter of which is further
divided into the P1 and extremely variable P2 subdomains;
they contain sites important for host cell interaction (Cao
et al., 2007). Ninety dimeric VP1 proteins form the outer
layer of the icosahedral virus particle, which can vary in
size from ∼27 to 40 nm, depending on the genotype (Vinje,
2015). VLPs are self-assembled by the recombinant capsid
protein VP1. As a high-yield NoV cell culture system is
still elusive (Jones et al., 2015), NoV VLPs are essential for
structural and immunogenicity studies, and they are considered
promising vaccine candidates (Blazevic et al., 2011; Atmar et al.,
2015).
Norovirus infections occur early in life (Hinkula et al.,
1995; Nurminen et al., 2011) and antibody seroprevalence
reaches almost 100% by adulthood (Jing et al., 2000; Carmona-
Vicente et al., 2015). Multiple sequential infections by genetically
distinct NoV strains have been reported to occur frequently,
especially in young children (Saito et al., 2014; Blazevic et al.,
2015b). According to most studies, the duration of protection
in adults is relatively short and limited to genetically similar
virus strains (Wyatt et al., 1974; Johnson et al., 1990; Simmons
et al., 2013). There is controversy over the correlates of
protective NoV immunity and the length and specificity of the
protection, which is complicated by the genetic diversity of
NoVs (Siebenga et al., 2009; Vinje, 2015) and differences in
the pre-existing NoV immunity of humans (Lindesmith et al.,
2010, 2015). Furthermore, the distinctive expression pattern of
polymorphic HBGAs affects individual susceptibility to NoV
infections (Lindesmith et al., 2013). HBGAs, found, e.g., on the
respiratory and gastrointestinal tract surface epithelia and in
bodily secretions, are recognized and bound by NoV particles
in a genotype-specific manner (Uusi-Kerttula et al., 2014) and
putatively serve as the initiation site for NoV infection (Hutson
et al., 2002; Huang et al., 2003; Cao et al., 2007). Serum IgG
antibody titers blocking NoV VLP binding to HBGA have been
most frequently associated with protection from NoV infection
and disease (Reeck et al., 2010; Nurminen et al., 2011; Malm
et al., 2014; Atmar et al., 2015). Humoral immunity to homotypic
strains is efficiently elicited (Malm et al., 2014), and broadly
cross-reactive NoV-specific IgG antibodies are found after NoV
exposure (Rockx et al., 2005; Lindesmith et al., 2010; Malm et al.,
2014). However, the induction of cross-protective antibodies
capable of blocking NoV VLP-HBGA binding interaction have
been observed only to a certain degree between the different
genotypes of the GII or GI genogroups, but not across the
genogroups (Reeck et al., 2010; Atmar et al., 2015; Blazevic
et al., 2015c). Additionally, mucosal IgA responses have been
associated with the blocking activity of NoV-HBGA binding
(Tamminen et al., 2016) and protection from infection and
NoV gastroenteritis (Lindesmith et al., 2003; Ramani et al.,
2015).
While most NoV immunity studies have focused on humoral
immune responses (Ramani et al., 2016), only three studies have
gathered information on the role of cell-mediated immunity
(CMI), especially T cells in NoV infection (Tacket et al., 2003;
Lindesmith et al., 2005, 2010). Control of the pathogenesis
with several viral infections, such as HIV-1 (Rosenberg et al.,
1997; Blazevic et al., 2000; Seder et al., 2008), the influenza
virus (Wilkinson et al., 2012; La Gruta and Turner, 2014),
and the human papilloma virus (Stanley, 2006), is known to
be dependent on T cell-mediated immunity, especially CTLs.
Therefore, T cells are also likely to play an important role
in NoV clearance. Following NoV infection/challenge, IFN-γ
secretion by CD4+ T cells has been analyzed only by ELISAs
using NoV VLPs as antigens, and the results indicated the
generation of NoV-specific memory T cell responses (Lindesmith
et al., 2005, 2010). Furthermore, the essential role of T
cells in controlling NoV infections has been provided by
studies with murine NoV (Chachu et al., 2008; Tomov et al.,
2013).
In the present study, we employed ELISPOT IFN-γ and ICS
assays to study ex vivo NoV-specific T cell responses in adult
human subjects for the first time. We used 18-mer synthetic
peptides derived from the NoV GII.4 sequence organized into
matrix peptide pools to identify NoV-specific T cell epitopes.
MATERIALS AND METHODS
Human Blood Donors
Venous blood samples (30 ml) were obtained from eight
healthy adult (age range 26–56, Table 1) volunteers (laboratory
personnel) with no symptoms of acute gastroenteritis in the
past year. Additional blood of two volunteers (Donors 2 and 4)
was collected for subsequent ICS experiments. Informed consent
was obtained from each volunteer prior to the sample collection
in accordance with the Declaration of Helsinki. No approval
by an ethical committee was needed. PBMCs were isolated
from the heparinized blood samples within 6 h of collection
by Ficoll-Paque PLUS (GE Healthcare, Little Chalfont, UK)
density gradient and suspended in cell medium (CM) containing
RPMI 1640 with Glutamax R© and HEPES (GibcoTM by Thermo
Fisher Scientific, Waltham, USA) supplemented with 10 µg/ml
Gentamicin (GibcoTM) and 10% fetal bovine serum (FBS, Sigma–
Aldrich, St. Louis, MO, USA). Plasma was collected from each
donor’s blood sample and stored at −20◦C until further use.
Human leukocyte antigen (HLA) typing was done by HLA locus-
specific amplification by PCR and the subsequent probing of the
product by sequence-specific oligonucleotide probe (PCR-SSOP,
ProImmune Ltd., Oxford, UK).
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TABLE 1 | T cell interferon gamma (IFN-γ) responses to NoV antigens.
Donor # Age(years) CM GII.4-99 VLP GII.4 SYD VLP GI.3 VLP GII.4-99 peptide poola CEF peptide pool OVA peptide
1 38 13b 80 63 128 90 355 15
2 35 0 10 15 8 268 225 0
3 56 3 50 53 90 80 1345 3
4 36 0 23 50 75 640 1390 3
5 47 0 18 23 20 28 763 3
6 44 3 60 33 38 95 1698 15
7 26 8 55 50 170 140 1248 8
8 45 10 50 35 40 58 325 18
aGII.4-99 complete peptide pool containing 76 single peptides. bMean spot forming cell (SFC) values per 106 PBMCs of parallel wells in ELISPOT IFN-γ assay. Positive
SFC (≥50 SFC) are bolded. VLP, virus-like particle; CM, cell media; CEF, cytomegalovirus, Epstein–Barr Virus and Influenza virus; OVA, ovalbumin; SFC, spot-forming
cells; SEM, standard error of the mean.
Recombinant Proteins
Norovirus VP1 genes of the ancestor GII.4-1999 (GII.4-99,
reference strain accession no: AF080551), the most recent GII.4
Sydney (SYD, accession no: AFV08795.1), and the representative
genotype of GI genogroup, GI.3-2002 (accession no: AF414403),
were cloned into pFastBac1 vector (Invitrogen, Carlsbad, CA,
USA) and transfected in Spodoptera frugiperda (Sf)9 insect cells
(Invitrogen) as described in detail elsewhere (Blazevic et al.,
2011). The amplified BV stocks were used (multiple of infection,
MOI = 1) for the production of NoV VP1 proteins in Sf9 cells
which self-assembled into VLPs (Figure 1). The harvested VLPs
were purified by two consecutive discontinuous sucrose gradient
ultracentrifugations as previously described (Huhti et al., 2010).
The residual sucrose was removed from the VLP preparations
by dialysis against a PBS followed by a concentration step with
Amicon Ultra-30 filtering units (Merc Millipore, Billerica, MA,
USA). The protein concentrations of the purified VLP stocks
were determined by BCA Protein Assay (PierceTM by Thermo
Fisher Scientific). The purity, morphology, and in vitro and
in vivo antigenicity of the VLPs were analyzed by sodium dodecyl
sulfate polyacrylamide gel electrophoresis, electron microscopy
(EM, Figure 1), ELISA, and mouse immunization experiments as
earlier published by our laboratory (Huhti et al., 2010; Blazevic
et al., 2011; Uusi-Kerttula et al., 2014; Malm et al., 2015).
Synthetic Peptides
Seventy-six individual synthetic peptides designated 99-1 to 99-
76 representing the entire 539 amino acid (aa) sequence of GII.4-
99 NoV VP1 were synthetized (Synpeptide Co. Ltd, Shanghai,
China) as 18-mers with adjacent peptides overlapping by 11
aa. The purity exceeded 70%, as determined by high pressure
liquid chromatography. Each lyophilized peptide was dissolved in
dimethyl sulfoxide (DMSO, Sigma–Aldrich) and further diluted
in sterile PBS (Lonza, Basel, Switzerland) for use in the assays.
The amount of DMSO never exceeded 0.01% in the final
medium. A complete peptide pool (containing all 76 peptides)
and 18 two-dimensional matrix pools (M1–M18) were made
from individual peptides as previously described (Wilkinson
et al., 2012). The first dimension included nine pools (M1–M9),
the second dimension also included nine pools (M10–M18), and
each pool contained eight or nine individual peptides so that each
peptide was present in two different matrix pools. A CEF peptide
pool (CTL Europe GmbH) containing 32 viral T cell epitopes
from the human cytomegalovirus virus, the Epstein–Barr virus,
and the influenza virus was used as a positive control peptide
pool (Currier et al., 2002) in the ELISPOT assays. A murine T
cell epitope (McFarland et al., 1999) derived from OVA (323–
339, Invivogen, San Diego, CA, USA) was used as an irrelevant
negative control peptide in the assays.
Norovirus-Specific Serology Assay
An ELISA was utilized to detect the NoV GII.4-99-, GII.4
SYD-, and GI.3-specific IgG antibodies in the human samples
as previously described (Malm et al., 2014). In brief, plasma
diluted serially starting at 1:100 was added to NoV VLP-coated
(25 ng/well) half-area 96-well plates (Corning Inc., Corning, NY,
USA) and incubated for 1h at +37◦C. One known NoV-positive
and -negative human serum was added to each plate as controls.
Blank wells lacking a sample were added as background controls.
The bound antibodies were detected by HRP conjugated anti-
human IgG (Novex R© by Thermo Fisher Scientific) reacting with
o-phenylenediamine dihydrochloride substrate (OPD, Sigma-
Aldrich). The OD values of each well were measured in a
microplate reader (Victor2 1420, Perkin Elmer, Waltham, MA,
USA). The results are expressed as the end-point titers of the
individual plasma determined as the highest titer giving an
OD value above the set cut-off value (mean OD for negative
control wells + 3 × SD and at least 0.100 OD) after background
subtraction.
ELISPOT IFN-γ Assay
Fresh PBMCs of the eight donors were assayed in an ELISPOT
assay for IFN-γ production upon stimulation with NoV VLPs
(GII.4-99, GII.4 SYD, and GI.3) or synthetic GII.4-99 peptides
used as a complete peptide pool, peptide matrices, and in
subsequent experiments as single peptides. Ninety-six-well
nitrocellulose filter plates (Millipore) were coated at +4◦C (18–
72 h) with anti-human IFN-γ capture antibody (Mabtech) at
a concentration of 5 µg/ml. After washing with sterile PBS,
the plates were blocked for 2–3 h with CM containing 10%
FBS. The antigens were added to the plates: VLPs at final
concentrations of 0.5 and 5 µg/ml and GII.4-99 peptide pools
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FIGURE 1 | Electron microscopy image of baculovirus-insect cell system-produced and sucrose gradient-purified norovirus GII.4-99 (A), GII.4 Sydney
(B), and GI.3 (C) virus-like particles (VLPs). VLPs were negatively stained with 3% uranyl acetate (pH 4.5) and the preparations were examined using an FEI
Tecnai F12 electron microscope at a magnification of 23,000×.
at 2 µg/ml. The dilutions of the final peptide pools used in the
assay were determined from earlier titration experiments. The
single peptides were used at 0.5–4 µg/ml final concentration.
Positive control (CEF-pool, at 1.5 µg/ml) and negative control
(OVA 323–339, at 2 µg/ml) peptides and CM only (background
control) were tested on each plate. Fresh PBMCs were added at
0.2 × 106 cells/well and the plates were incubated for 44 h at
+37◦C and 5% CO2. After discarding the cells, the plates were
washed and biotinylated anti-human IFN-γ antibody (Mabtech)
was added at 2 µg/ml. The plates were incubated for 3 h at RT
followed by 1 h incubation with 1:500 diluted streptavidin-HRP
(BD, Trenton, NJ, USA). The spots were developed for 7.5 min
with Vector Nova Red substrate (Vector Labs, Burlingame,
CA, USA) in the dark and the reaction was stopped with
tap water. The plates were air-dried prior to automated spot
counting by an ImmunoSpot Series II analyzer (CTL Europe,
Leinfelden-Echterdingen, Germany). The results are expressed as
mean SFC/106 PBMCs of the duplicate wells. The results were
considered positive if the number of SFC per well was ≥50
spots/106 PBMCs and twice above the background control (CM
only wells). SFC in the background control wells never exceeded
15 SFC/106 PBMCs.
Intracellular Cytokine Staining (ICS)
An ICS assay was employed to measure IFN-γ, TNF-γ and IL-
2 cytokine production, and to determine the T cell phenotype
responsible for cytokine secretion. Fresh PBMCs of two donors
were stimulated (1 × 106 cells/condition) with 2 µg/ml 99–20
single peptide or with 1 µg/ml SEB (Sigma) in the presence of
1 µg/ml CD28 and 1 µg/ml CD49d costimulatory antibodies
(BD Biosciences, San Jose, CA, USA) for 2 h at 37◦C. As a
control, PBMCs were incubated in CM only supplemented with
the costimulatory antibodies. The protein transport inhibitor
brefeldin A (GolgiPlug, BD Biosciences, San Jose, CA, USA) at
a concentration of 10 µg/ml was added and the incubation was
continued for 16 h. After the stimulation, cells were treated with
EDTA for 15 min to arrest activation and remove adherent cells,
and washed with FACS Stain buffer. Non-specific binding was
blocked by incubating the cells for 10 min with Human BD Fc
Block. Cell surface markers CD3 and CD8 were stained before
the permeabilization of the cells by incubating the cells with
monoclonal antibodies against human CD3 (clone UCHT1, FITC
conjugate) and CD8 (clone RPA-T8, PerCP-Cy5.5 conjugate)
in 50 µl Stain buffer for 30 min on ice in the dark. Cells
were washed twice with Stain buffer and treated with BD
Fixation/Permeabilization solution for 20 min according to the
manufacturer’s instructions. Fixed and permeabilized cells were
washed twice with BD Perm/Wash buffer before intracellular
staining with the mixture of IFN-γ (clone 4S.B3) phycoerythrin
(PE)-Cy7-conjugate, IL-2 (clone MQ1-17H12) phycoerythrin-
conjugate, and TNF-α (clone MAb11) APC-conjugate in 50 µl
Perm/Wash buffer for 30 min on ice in the dark. After the ICS
incubation period, PBMCs were washed twice with Perm/Wash
buffer and resuspended in Staining Buffer for acquisition and
analysis. All reagents used for ICS were purchased from BD
Pharmingen (San Jose, CA, USA).
Flow Cytometric Analysis
Samples were acquired using a 2-laser FACS CantoII flow
cytometer (BD) and FACSDiva Software V 6.1.3 (Becton
Dickinson, Heidelberg, Germany) within 2 h of staining with
fluorescent antibodies. PMT voltages were adjusted with the
unstained, fixed PBMC sample. At least 70,000 CD3+ cells
were acquired per sample. The gates were designed in the
negative control sample with consideration of the marker
downregulation from the stimulated samples. The gating
strategy is shown in Figure 2. The final analysis plots of
IFN-γ IL-2, and TNF-α were gated on CD3+CD8+ and
CD3+CD8− populations. The data analysis was performed
using FlowJo software version 10.1 (Tree Star, San Carlos,
CA, USA). Cytokine responses were defined as positive if
the percentages of cytokine-positive cells stimulated with the
antigens were at least two times higher and >0.05% above the
cytokine positive cells in the background (CM; Ferrari et al.,
2004).
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FIGURE 2 | The gating strategy for flow cytometry analysis from representative data. PBMCs from a donor were stimulated with SEB for 16 h in the
presence of brefeldin A and then stained for IFN-γ and lineage markers CD3 and CD8. A forward and side scatter was used for gating the lymphocyte population.
CD3+ lymphocyte population was further gated to CD8+ and CD8− populations and IFN-γ staining was analyzed for both populations as previously described by
others (Meddows-Taylor et al., 2007). Dot plots show gated populations and events as percentages of the parent population.
Statistical Analyses
Fisher’s exact test was used to compare the differences in the
IgG end-point titers. The Mann–Whitney U-test was used to
assess the differences between NoV VLP- and GII.4-99 peptide
pool-induced SFC/106 PBMCs in the ELISPOT. Spearman’s
rank correlation coefficient was used to examine the correlation
between the SFC/106 PBMCs and the antibody end-point titer.
Statistical analyses were performed using IBM SPSS Statistics
(SPSS, Chicago, IL, USA) version 23.0. Statistical significance
was defined as p < 0.05. All hypothesis tests were two-
tailed.
RESULTS
Antibody Responses
NoV GII.4-99, GII.4 SYD, and GI.3 VLPs were used as antigens
in an ELISA to test plasma IgG antibody binding to native,
conformational antigenic determinants. The results showed that
all eight donors had NoV-specific antibodies (Figure 3A),
indicating previous NoV exposure, but the magnitude of the
genotype-specific responses varied among the donors. All donors
had antibody response to GII.4-99, and the end-point titers to this
genotype were the highest of the three VLPs tested (Figure 3B,
p< 0.05).
T Cell Response to NoV VLPs and Capsid
Peptide Pool
An ELISPOT assay was utilized to detect ex vivo IFN-γ release
from human PBMCs after in vitro stimulation for 44 h with
NoV VLPs (GII.4-99, GII.4 SYD, and GI.3) or a complete peptide
pool derived from GII.4-99 capsid VP1. None of the donors
responded to stimulation with 0.5 µg/ml VLPs (data not shown).
Table 1 shows that when using a high concentration (5 µg/ml)
of the VLPs, six of the eight donors responded to at least one
VLP, and three donors produced IFN-γ in response to all VLPs
tested. Interestingly, all but one donor (#5) responded to the
GII.4-99 peptide pool, but only five responded to GII.4-99 VLPs
(Table 1). Furthermore, the number of IFN-γ-secreting cells
in response to the peptide pool was higher (mean 175 ± 71.2
SFC/106 cells) than the response to the corresponding GII.4-
99 VLPs (mean 43 ± 8.5 SFC/106 cells; p < 0.05). However,
there was a difference in the magnitude of these responses
in each individual and high variation among the donors was
seen, especially with the peptide pool stimulation (58–640 mean
SFC/106 PBMCs). Two donors (#2 and #4), who were the
best responders to the GII.4-99 peptide pool, had no response
to the VLPs of the same origin. Only one donor (#5) did
not respond either to the VLP or peptide pool stimulation.
PBMCs of all eight donors produced IFN-γ after the CEF
peptide pool stimulation (>200 SFC/106 PBMCs) and none
responded to the negative OVA control peptide (<20 SFC/106
PBMCs).
Correlation of T Cell and Antibody
Responses
Next, we determined whether NoV VLP-specific antibody titers
correlated with the corresponding genotype T cell responses
detected in the ELISPOT IFN-γ assays (Figure 4). No correlation
(p > 0.05) was observed between GII.4-99 antibody titers and
IFN-γ-producing PBMC numbers after the VLP (Figure 4A)
or complete peptide pool (Figure 4B) stimulation. Similarly,
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FIGURE 3 | Norovirus genotype-specific immunoglobulin G (IgG) antibody titers. The plasma of eight donors was used to determine individual end-point titer
(A) and geometric mean titers (GMTs) with 95% confidence intervals (B) against NoV GII.4-1999, GII.4 Sydney, and GI.3 VLPs in an enzyme-linked immunosorbent
assay (ELISA). Statistical significance was determined by Fisher’s exact test, and a p-value ≤ 0.05 was considered to be statistically significant (∗).
FIGURE 4 | Correlation of GII.4-1999-specific antibody and T cell responses. Spearman’s rank correlation (r) was determined between the norovirus
GII.4-1999-specific antibody titer and ELISPOT IFN-γ spot-forming cell (SFC)/106 peripheral blood mononuclear cells (PMBCs) in response to GII.4-99 VLPs (A) and
a complete capsid peptide pool (B) stimulation.
no correlation was detected between antibody titers and IFN-
γ-secreting cell numbers against GII.4 SYD (r = −0.268,
p= 0.521) or GI.3 (r = 0.328, p= 0.618) VLPs (data not shown).
Mapping of T Cell Epitopes with Matrix
Peptide Pools
Seventy-six 18-mer overlapping peptides spanning the entire
GII.4-99 VP1 were used to identify NoV-specific T cell epitopes.
PBMCs of each donor were assayed for IFN-γ production in an
ELISPOT assay in response to the peptides organized into 18
matrix pools (M1–M18). Only three of the eight donors (donors
#2, #4, and #7) responded to at least two matrix pools (Figure 5),
and the same donors also had the strongest response to the
complete GII.4-99 peptide pool (Table 1). The strongest peptide-
specific IFN-γ response was toward matrix pools M2 and M12 in
donors #2 and #4. Donor #4 also responded moderately to matrix
pools M7 and M11, as did donor #7 to M4 and M13 (Figure 5).
For each donor responding to the matrix pools, stimulatory
peptides contained in the pools were deconvoluted from a two-
dimensional matrix system, where each peptide appeared only
once in each dimension. Three single peptides were identified as
putative T cell epitopes: 99-16 peptide (aa 106-123) included in
the M7 and M11 pools (donor #4), 99-20 peptide (aa 134-151)
included in the M2 and M12 pools (donors #2 and #4), and 99-31
(aa 211-228) in the M4 and M13 pools (donor #7).
T Cell Restriction of the Epitopes
In the three donors with the T cell epitopes deconvoluted
from a two-dimensional matrix system, newly isolated PBMCs
were stimulated with the single peptides 99-16, 99-20, and
99-31 in the second ELISPOT IFN-γ assay. Only peptide
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FIGURE 5 | Enzyme-linked immunosorbent spot interferon gamma (IFN-γ) responses to GII.4-1999 matrix peptide pool stimulation. Peripheral blood
mononuclear cells (PBMCs) of eight donors (#1-8) were stimulated with 76 18-mer GII.4-99 capsid-derived single peptides organized into 18 matrix pools (M1–M18)
or left unstimulated (CM, culture media). Shown are the mean spot-forming cells (SFC)/106 PBMCs of two replicate wells with the standard errors of the mean. The
cut-off line (dotted line) represents the positive SFC/106 value of >50 SFC/106 cells.
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FIGURE 6 | Enzyme-linked immunosorbent spot IFN-γ responses toward NoV GII.4-1999 T cell epitope 99-20. Fresh peripheral blood mononuclear cells
(PBMCs) of donors #2 (A) and #4 (B) were stimulated with an increasing concentration (0–4 µg/ml) of peptide 99-20 containing the putative NoV-specific T cell
epitope. Shown are the spot-forming cells (SFC)/106 PBMCs of two replicate wells with standard errors of the mean. The cut-off line (dotted line) represents the
positive SFC/106 value of >50 SFC/106 cells.
99-20 (134SPSQVTMFPHIIVDVRQL151) induced strong IFN-γ
production in donors #2 (Figure 6A) and #4 (Figure 6B), who
originally responded strongly to the M2 and M12 matrix pools
(Figure 5 and data not shown).
Peptide 99-20 was further tested by ICS to identify the T cell
subset responsible for IFN-γ production in donors #2 and #4
determined by the ELISPOT assay. Additionally, IL-2 and TNF-α
cytokine secretion were simultaneously analyzed. Fresh PBMCs
were stimulated with the peptide 99-20 or SEB as a positive
control antigen. The unstimulated PBMCs (CM) sample served
as a background control. The percentages of cytokine-producing
cells were determined within the CD3+CD8+ and CD3+CD8−
(CD4+) T cell populations. Peptide 99-20 induced the expression
of all three cytokines by CD3+CD8+ T cells for both donors
(Figure 7), identifying the epitope as CD8+ T cell-restricted.
These two donors were further typed for the HLA-A, -B, and
-C alleles in order to identify possible common HLA class I
restricting molecule binding to the peptide epitope 99-20. The
typing results showed that both donors carry HLA-A∗02:01 allele.
Further analysis of the cells responding to peptide 99-20 by
IFN-γ production (gating on CD3+CD8+IFN-γ+ lymphocytes)
revealed that∼74% of these populations in both donors were also
simultaneously expressing IL-2 and TNF-α cytokines. No positive
responses were found in the CD4+ T cell gate for any of the
cytokines after the 99-20 peptide stimulation (data not shown).
Both the CD3+CD8+ and CD3+CD8− T cell populations of
each donor were positive for all cytokines after SEB stimulation,
confirming the good viability and functionality of the cells and a
successful staining protocol (Figure 2 and data not shown).
DISCUSSION
Very limited published information is available on natural T
cell immunity in NoV-infected humans (Tacket et al., 2003;
Lindesmith et al., 2005, 2010). CD4+ Th and CD8+ CTLs
are important in protection from infection by different viruses,
including influenza (La Gruta and Turner, 2014; Lartey et al.,
2015), HIV (Rosenberg et al., 1997; Blazevic et al., 2000), HPV
(Stanley, 2006), and the Epstein–Barr virus (Pepperl et al.,
1998). Protective immunity to NoV might also be partially
dependent on the activation of T cell immunity. Murine NoV
establishes persistent infection in the absence of functional T
cells, supporting the importance of T cell-mediated immunity in
NoV infection (Wobus et al., 2006; Chachu et al., 2008; Tomov
et al., 2013).
We studied antibody and T cell-mediated pre-existing
immune responses in eight healthy adult donors. Each donor
had a positive serum IgG antibody titer against all NoV
VLPs tested, indicating previous exposures to the NoV (Jing
et al., 2000; Nurminen et al., 2011; Carmona-Vicente et al.,
2015). Two NoV GII.4 VLPs, derived from an ancestor GII.4-
99 and the most recent GII.4 SYD variants, were chosen as
antigens, as GII.4 has been the dominating NoV genotype for
over two decades (Bull and White, 2011; Eden et al., 2014).
GI.3 VLPs were chosen as a representative genotype of the
GI genogroup contributing to a minority of NoV infections
in humans (Matthews et al., 2012). The strongest antibody
response in seven of the eight donors was detected toward
GII.4-99 VLPs, suggesting that most of the donors have been
exposed to GII.4-99 or antigenically closely related variants in
the past. As these donors have likely not experienced infection
with the recently circulating GII.4 SYD, the antibody responses
to this genotype were significantly lower, probably consisting
of cross-reactive antibodies raised to the earlier circulating
variants of the GII.4 genotype (Rockx et al., 2005; Malm et al.,
2015).
Different methods are employed to measure T cell responses
in natural infections and vaccination studies. ELISPOT and ICS
detecting IFN-γ secretion from PBMCs induced by synthetic
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FIGURE 7 | Expression of IFN-γ, IL-2, and TNF-α by intracellular staining after stimulation with NoV GII.4-1999 peptide epitope 99-20. Peripheral blood
mononuclear cells (PBMCs) of donors #2 having A∗01:01/∗02:01; B∗08:01/∗56:01; C∗01:02/∗07:01 HLA class I phenotype alleles (A) and #4 having
A∗02:01/∗32:01; B∗35:01/∗40:02; C∗03:04/∗04:01 HLA class I phenotype alleles (B) were stimulated with 2 µg/ml of 99-20 single peptide for 16 h and the cytokine
response was measured by flow cytometry. PBMCs in culture media only (CM) (left panel) and peptide-stimulated PBMCs (right panel) were gated to CD3+CD8+ T
cells and the percentages of IFN-γ, IL-2, or TNF-α cytokine-expressing cells are indicated.
peptides and/or recombinant whole proteins are the most
commonly used (Schmittel et al., 2001; Currier et al., 2002;
Kutscher et al., 2008; Streeck et al., 2009; Freer and Rindi, 2013;
Kutscher et al., 2013; Lartey et al., 2015). In comparison to
ICS, ELISPOT is highly sensitive but does not identify the cell
type responsible for the cytokine production (Tassignon et al.,
2005; Tobery et al., 2006). Therefore, using ICS to complement
results from an ELISPOT assay is a worthwhile and generally
used practice (Freer and Rindi, 2013; Lartey et al., 2015).
To study T cell-mediated immunity, we investigated ex vivo
IFN-γ production from freshly isolated PBMCs in response to
stimulation with NoV VLPs and GII.4-99 synthetic peptides by
both ELISPOT IFN-γ and ICS. We detected a much higher
frequency and magnitude of T cell responses using an ELISPOT
IFN-γ assay in previously exposed adult human donors toward
synthetic peptides (pooled and individual) than the whole protein
assembled in the VLPs. All but one donor responded to the
complete GII.4-99 peptide pool, but only five responded to GII.4-
99 VLPs. Furthermore, two donors had a strong CD8+ T cell
response to GII.4-99-specific peptide 99-20, but no response to
the corresponding VLPs, as shown by the ELISPOT IFN-γ.
The greater response to the peptides than VLPs detected
here is not surprising, as the 15-20-mer synthetic peptides
added exogenously to the PBMCs circumvent the need for
antigen processing by directly binding to HLA classes I and
II molecules and stimulating both CD4+ and CD8+ T cells
efficiently (Blazevic et al., 1995; Kern et al., 2000; Kaufhold
et al., 2005). In contrast, protein antigens require processing
into smaller peptide fragments by antigen-presenting cells before
being presented for T cell recognition, preferentially stimulating
CD4+ T cells through HLA class II molecules. The ELISPOT
assay employing peptides usually requires overnight incubation
(Schmittel et al., 2001; Kaufhold et al., 2005). Therefore, we used
a 44 h assay to ensure processing of the VLPs and the binding
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of the peptide fragments to HLA molecules. Comparison of
the assays performed at 20 or 44 h showed that NoV peptide-
induced responses were comparable but the responses to the
VLPs were slightly improved by a longer incubation period (data
not shown). The absence of NoV seronegative samples implies
problems in setting the cut-off for true positives and warrants
further studies with the samples where the T cell response is
absent, such as cord blood samples.
The 18-mer epitope 99-20 (134SPSQVTMFPHIIVDVRQL151),
which induced strong IFN-γ, IL-2, and TNF-α production by
CD8+ T cells in two donors, may be restricted to an identical
HLA class I molecule shared between these two subjects or
may contain overlapping epitopes restricted by different HLA
class I molecules. Indeed, the HLA typing of the two donors
identified the HLA-A∗02:01 as a possible restriction allele as
both subjects carry this molecule. To fully describe the minimal
epitope sequence and to confirm its restriction, future work is
necessary. As the adjacent overlapping peptides (99-19 and 99-
21, respectively) did not elicit IFN-γ responses (data not shown),
the minimal T cell epitope is probably not contained in the
overlapping 11 aa peptide segments. As optimal CD8+ T cell
epitopes are 9 aa long (Kiecker et al., 2004; Murphy et al., 2007),
mapping studies using peptides of a shorter length are required
to identify the minimal epitope. Congruently, peptide binding
predictions using the IEDB analysis resource and ANN (Nielsen
et al., 2003; Lundegaard et al., 2008) and SMM (Peters and Sette,
2005) tools showed that the 10 aa sequence 139TMFPHIIVDV148,
contained in the 18-mer peptide 99-20, has a high affinity binding
(IC50 < 100 nM) to the HLA-A∗02:01 allele. Simultaneous
production of these cytokines by NoV-specific CD8+ T cells
indicates the generation of multifunctional memory T cells after
natural infection. It was previously shown that human central
memory CD8+ T cells – but not effector memory T cells –
produce IFN-γ and IL-2 in response to virus epitopes (Mallard
et al., 2004). These multifunctional T cells have been shown to be
highly relevant for conferring protection from infections such as
influenza (Seder et al., 2008; La Gruta and Turner, 2014; Lartey
et al., 2015).
The 99-20 epitope is situated in the S domain of the capsid VP1
and is highly conserved between distant GII.4 variants. There is
only 1 aa change in the sequence between the GII.4-99 and GII.4
SYD (145I to 145V). The 18 aa-long peptide sequence is highly
specific to the GII.4 genotype and differs by five aa from other
GII NoVs, including the GII.1, GII.2, GII.3, GII.12, and GII.17
genotypes; the aa at positions 136 (S), 138 (V), and 144 (I) are
variable in all aligned GII strains.
In this study, no correlation was found between pre-existing
NoV-specific antibody levels and T cell responses, however,
the small sample size makes it difficult to interpret the
absence of correlation. In contrast to the antibody responses,
our results indicate that natural T cell immunity to NoV is
quite weak. Congruently, limited information published thus
far (Tacket et al., 2003; Lindesmith et al., 2010) has shown
virtually undetectable baseline levels of NoV-specific T cell
responses prior to challenge or immunization. The mapping
studies performed here to detect the production of IFN-γ to
synthetic peptides by the PBMCs of adult donors exposed
to NoV in the past revealed a limited number of dominant
T cell stimulatory epitopes in the NoV GII.4 capsid protein.
Three putative T cell epitopes were identified using matrix
pools, located in the S domain (peptide 99-16, aa 106-123 and
peptide 99-20, aa 134-151) and at the junction of the S and
P1 domains (peptide 99-31, aa 211-228) of the NoV capsid,
but only one epitope was confirmed with the use of single
peptides in the ELISPOT assay. Intramuscular immunization
of mice of a single haplotype (H-2d) with GII.4-99 VLPs
induced responses to seven peptide epitopes located alongside
the capsid VP1 (unpublished observation), which is more than
seen in the eight NoV-exposed human donors. Studies on
recently exposed individuals or young children are needed to
elucidate if NoV-specific T cell response differs after recent
infection. It also remains to be seen if the NoV vaccination
would induce novel epitopes to broaden the T cell responses in
humans or/and increase the frequency of already existing NoV-
specific T cells. Additionally, gut-associated lymphoid tissue
needs to be investigated to determine T cell responses in
the gut, which may be different from the peripheral blood T
cells.
Short-lived antibody responses to NoV described previously
(Johnson et al., 1990; Simmons et al., 2013; Blazevic et al.,
2015a), together with a restricted memory T cell response to NoV
described here, may be responsible for repeated NoV infections
over an individual’s life time. Blocking (neutralizing) antibodies
are the most recognized correlate of protection against NoV
infection, and their activity is measured in current clinical trials
with VLP-based vaccine candidates (Lindesmith et al., 2015;
Ramani et al., 2016). Protection against NoV probably reflects
the sum of various immune responses, including antibody and
T cell responses. Therefore, measuring both arms of the adaptive
immunity should be undertaken in clinical trials. More studies on
NoV-specific T cell responses are needed to determine their role
in protection from infection.
This article describes for the first time an ELISPOT IFN-
γ method using synthetic peptides to measure NoV-specific T
cell responses from freshly isolated PBMCs. In addition, we
identified the first human NoV-specific CD8+ T cell epitope
(134SPSQVTMFPHIIVDVRQL151) using this approach.
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